NEVVI Medicare utilization intelligence
or

← back

Provider profile

CLEVELAND, JOSEPH

Hematology-Oncology · NPI 1992209381 · SAN LUIS OBISPO, CA

1
Groups
23
Codes · 2024
6,699
Disclosed services

CLEVELAND, JOSEPH is a Hematology-Oncology in SAN LUIS OBISPO, CA, a member of 1 medical group, who billed 23 distinct codes to Medicare Part B in 2024.

Groups: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (LOS ANGELES, CA)

Year: 2024

Provider overview · all codes · CY2024

6,699
disclosed services
23
codes billed to Medicare Part B

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
J1561 Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
96413 Administration of chemotherapy into vein, 1 hour or less
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J2469 Injection, palonosetron hcl, 25 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J3489 Injection, zoledronic acid, 1 mg
96372 Injection of drug or substance under skin or into muscle
36415 Insertion of needle into vein for collection of blood sample
J7050 Infusion, normal saline solution, 250 cc
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96375 Injection of additional new drug or substance into vein
96417 Administration of additional new drug or substance into vein, 1 hour or less
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96523 Irrigation of implanted venous access drug delivery device

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.